Adaptive Biotechnologies Corp
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $41,873 | $37,647 |
| Operating expenses | ||
| Cost of revenue | 18,051 | 18,681 |
| Research and development | 30,245 | 32,601 |
| Sales and marketing | 22,319 | 22,308 |
| General and administrative | 19,597 | 20,831 |
| Amortization of intangible assets | 423 | 419 |
| Total operating expenses | 90,635 | 94,840 |
| Loss from operations | (48,762) | (57,193) |
| Interest and other income, net | 4,222 | 3,024 |
| Interest expense | (2,993) | (3,531) |
| Net loss | (47,533) | (57,700) |
| Add: Net loss attributable to noncontrolling interest | 26 | 1 |
| Net loss attributable to Adaptive Biotechnologies Corporation | $(47,507) | $(57,699) |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $(0.33) | $(0.40) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | 145,787,527 | 143,511,142 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.